Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Molgramostim - Savara Pharmaceuticals

Next Previous
Drug Profile

Molgramostim - Savara Pharmaceuticals

Alternative Names: GM-CSF inhalation - Savara; MOLBREEVI; Molgradex; Nebulised recombinant human GM-CSF - Savara; NPC 23; rh-GM-CSF

Latest Information Update: 01 Sep 2025

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Serendex Pharmaceuticals
  • Developer Justus Liebig University Giessen; Savara Pharmaceuticals
  • Class Antibacterials; Antibronchitics; Antifibrotics; Antineoplastics; Chemoprotectants; Immunotherapies; Recombinant proteins
  • Mechanism of Action Granulocyte macrophage colony stimulating factor replacements
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Pulmonary alveolar proteinosis; Adult respiratory distress syndrome
  • New Molecular Entity No

Highest Development Phases

  • Preregistration Pulmonary alveolar proteinosis
  • Phase II Adult respiratory distress syndrome; SARS-CoV-2 acute respiratory disease
  • Discontinued Bronchiectasis; Cystic fibrosis; Nontuberculous mycobacterium infections

Most Recent Events

  • 01 Sep 2025 9448537: KDM, Clinical sec and HE updated
  • 20 Aug 2025 Efficacy and adverse events data from the phase III IMPALA-2 trial in Pulmonary alveolar proteinosis released by Savara Pharmaceuticals
  • 13 Aug 2025 Savara Pharmaceuticals anticipates completing the submission of Marketing Authorization Application (MAA) for Molgramostim for Pulmonary alveolar proteinosis (aPAP) in Europe and United Kingdom in quarter one of 2026

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top